Randal W. Scott - Dec 1, 2023 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Dec 1, 2023
Transactions value $
-$73,500
Form type
4
Date filed
12/5/2023, 04:00 PM
Previous filing
Sep 7, 2023
Next filing
Dec 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Sale -$28.5K -1K -7.41% $28.50 12.5K Dec 1, 2023 See Footnote F1, F2
transaction BBIO Common Stock Sale -$45K -1.5K -12% $30.00 11K Dec 1, 2023 See Footnote F1, F2
holding BBIO Common Stock 5K Dec 1, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
F2 By Thinking Bench Capital LLC.